Centrient Pharmaceuticals

About, Contact Details

EVENTS

Webinars & Exhibitions

PRESENTATION(s)

Product List 2022, Corporate Presentation, PNEC White Paper, ESG Report, API Product List 2022, FDF Product List 2022, GMP Certificate 2019, Centrient Acquires Astral SteriTech, Centrient Expanding Product Portfolio

VIDEO(s)

Corporate Video, Centrient Sustainability Ambitions, Centrient’s Amoxicillin Production, Cephalosporin by Centrient, Global Market Leader in Nystatin, Major Penicillin G Producer Outside China, Our Purpose, Statins API Producer, The Production of Our Statins, Centrient Pharmaceuticals Acquires Astral SteriTech

DIGITAL CONTENT

2 Interviews #SpeakPharma, 67 News

APIs // Active Pharmaceutical Ingredients

26 APIs, 8 USDMF, 15 CEP/COS, 5 JDMF, 7 EU WC, 23 KDMF, 8 NDC API, 22 Listed APIs

DEVELOPMENTS

No Content

DOSSIERs // Finished Dosage Formulations

49 Dossiers, 12 FDA Orange Book, 37 Listed Dossiers

KEY PRODUCTS

Amoxicillin Trihydrate, Atorvastatin, Caspofungin, Clavulanic Acid, Co-amoxiclav, Rosuvastatin, Rosuvastatin Calcium, Rosuvastatin Zinc

Amoxicillin Trihydrate
Atorvastatin
Caspofungin
Clavulanic Acid
Co-amoxiclav
Rosuvastatin
Rosuvastatin Calcium
Rosuvastatin Zinc

INTERMEDIATES

2 Listed Products

2 Listed Products

INSPECTIONS & REGISTRATIONS

11 FDA, 5 EDQM, 2 WHO-GMP, 2 GDUFA

All #SpeakPharma

“Centrient is at the forefront of sustainable pharmaceutical manufacturing”

One of the most pressing problems today is environmental pollution. Every year, the world comes together on April 22 to celebrate Earth Day. This year’s Earth Day calls on governments, institutions, businesses, and citizens to invest in the planet by addressing the issues of climate change, air and water pollution, deforestation, and plastic overconsumption. According to the World Health Organization (WHO), healthier environments can prevent almost a quarter of the world’s disease burden.This week, SpeakPharma spoke to Manjit Singh, Director for Corporate Sustainability at Centrient Pharmaceuticals, a global B2B leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, about sustainable manufacturing. Excerpts:How are pharma companies addressing the issue of environmental sustainability? What goals have you set for reducing your environmental impact?The global pharma industry is a major polluter. During the past decade, the intensity of greenhouse gas emissions generated by the pharma industry was approximately 55 percent greater than that of the automotive industry. The industry must work together to systematically consider the environmental impact of the products it manufactures.Today, many companies incorporate carbon emissions reduction, responsible waste and water management, and renewable energy sourcing as core environmental, social, and governance (ESG) goals. The growing demand for environmental sustainability also affects pharmaceutical companies’ supply chains and procurement practices.One of the biggest environmental issues we face as a society is CO2 emissions. It’s a major focus area for many companies. At Centrient, we have set a goal of reducing our carbon emission intensity by 50 percent by 2030 through increased reliance on renewable energy. We are committed to going through third-party assessments and ratings like EcoVadis and SBTi (Science Based Targets initiative) to be transparent about our progress towards emissions reduction targets.Another key issue is wastewater management. Pharmaceutical manufacturing, particularly antibiotic production, is a highly water-intensive process. We produce all our antibiotics using a proprietary enzymatic process. This process requires less water and energy and doesn’t use chemical solvents or other harmful substances.What is antimicrobial resistance, and how does it affect human health and the environment?Antimicrobial resistance or AMR occurs when bacteria, viruses, fungi, and parasites change over time and stop responding to medicines. Antibiotics and other antimicrobial drugs become ineffective, and infections become increasingly difficult or impossible to treat, making routine medical procedures, such as surgery — including C-sections, hip replacements, and organ transplantations — riskier. For example, AMR is the second leading cause of death in cancer patients.The WHO currently lists AMR among the top 10 threats to global health. By 2050, up to 10 million deaths could occur annually due to AMR.When it comes to pharmaceutical manufacturing, release of antibiotics in high concentrations from manufacturing sites can contribute to new forms of resistance in pathogens. In 2016, we became one of the first pharmaceutical companies to begin the continuous, year-round monitoring of antimicrobial activities in wastewater at all our sites in Europe and beyond. Since then, we have developed an innovative way of detecting very low antibiotic activity levels – as low as 50 parts per billion – in wastewater. In May 2022, we became the first pharma company to meet the stringent PNEC (short for Predicted No-Effect Concentration) discharge targets for our complete oral antibiotics product range and their supply chains. The final step in this process will be to obtain an external PNEC certification.We are one of the first companies to participate in a pilot certification scheme designed by the British Standards Institution (BSI) in collaboration with the AMR Industry Alliance.As a former chair of the Pharmaceutical Supply Chain Initiative (PSCI), what’s your view on the recent developments in sustainable procurement?Along with responsible manufacturing, the industry must ensure that the procured raw materials come from cleaner sources. Some European governmental agencies already incentivize responsible manufacturing and compliance while procuring antibiotics from suppliers. For example, at Centrient, our suppliers are assessed by PSCI-approved audit firms and in-house assessments. This covers labor and human rights, ethics, health and safety, the environment, and management systems.What are your sustainability tips for Earth Day?To make a positive impact on Earth Day, individuals can clean up their communities, plant more trees, reduce the use of plastic, and reuse and recycle more things. Similarly, manufacturers must consider the negative impact of their operations on the environment and make sustainability a part of their business strategy.At Centrient, our sustainability efforts are geared towards creating value for all our stakeholders, driving sustainable growth with our customers, and creating a more sustainable world for future generations.

Impressions: 2212

#SpeakPharma With Centrient Pharmaceuticals

21 Apr 2023

“Centrient focuses on innovative and sustainable manufacturing of medicines”

This week, SpeakPharma interviews two top executives from Centrient Pharmaceuticals — Gabriel Morelli, Chief Transformation and Strategic Planning Officer, and Judit Serra, Innovation Project Associate Director. Centrient Pharmaceuticals is a global B2B leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals. In 2021, the over 150-year-old pharma company facilitated more than 1.5 billion patient treatments. The duo talks about Centrient's track record in innovative and sustainable manufacturing of medicines, the company's strategy for the future and the recently established New Pipeline program. Can you briefly take us through Centrient’s history and vision? Gabriel Morelli: Our company was founded in 1869, and its story has been one of constant evolution and innovation. Known initially as Nederlandsche Gist- en Spiritusfabriek, the company was rechristened twice – as Gist Brocades and DSM Sinochem Pharmaceuticals – before being rebranded as Centrient Pharmaceuticals. We are currently a 2,200-people strong company with operations spread across four continents. Bain & Company has owned Centrient since 2018. Over the years, we have established ourselves as a global B2B leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals. We produce and sell intermediates, active pharmaceutical ingredients (APIs), tablets, capsules and other finished dosage forms (FDFs). We are an agile, evolving and ever-growing company. Our vision aligns with our company’s purpose of improving patients’ lives worldwide by capitalizing on our key strength – the innovative and sustainable manufacturing of medicines. We are customer-centred and aim to be the partner of choice for enzymatic development and manufacturing, offering a diversified portfolio of sustainably made products, cost efficiency and an integrated global network of manufacturing facilities. What are some of the sustainability initiatives Centrient has undertaken? Gabriel Morelli: We have a long history of innovation and leadership in sustainability. Centrient was one of the first companies in the world to produce antibiotics on an industrial scale shortly after World War II. Since then, we've changed how sustainable antibiotics are made by utilizing our innovative enzymatic platform – with more than 500 patents across nearly 80 patent families. First introduced in the market as the PureActives range of products, our proprietary platform replaces the traditional 13-step production process with more efficient, environment-friendly methods. Our simplified process requires less energy and water and avoids the use of harmful solvents and other chemicals. Between 2008 and 2020, we cut our carbon emissions by 50 per cent and energy and water consumption by 45 per cent and 25 per cent, respectively. As a pharmaceutical manufacturer, we also recognize the importance of responsible wastewater management. With our state-of-the-art wastewater treatment plants, water recycling programs and projects supporting local communities, we contribute to clean water and sanitation. Our scientists developed a highly sensitive method for detecting very low antibiotic activity levels in treated wastewater. We monitor and clean our wastewater to prevent the release of antibiotics into the environment, which may lead to antimicrobial resistance. According to the World Health Organization, antimicrobial resistance is one of the biggest threats to human health. Earlier this year, we achieved an important milestone in responsible manufacturing. We fully comply with the stringent Predicted No-Effect Concentration (PNEC) discharge targets developed and adopted by the AMR Industry Alliance. PNEC refers to the 'safe' concentration of antibiotics in water that is unlikely to cause adverse environmental risks due to the development of antimicrobial resistance. We are proud to produce essential medicines for patients worldwide while minimizing our impact on the environment, preventing antimicrobial resistance and supporting the communities in which we operate. Tell us about Centrient's New Pipeline program. Which new therapeutic areas does the company plan to enter? Judit Serra: In 2021, we initiated Centrient's New Product Pipeline program intending to reach out to more patients and meet the needs of our customers through new and innovative products. We have started work on expanding our core portfolio of antibiotics and statins by adding specific 'close-to-core' programs to broaden our customer offerings. This includes the statin Pitavastatin and some antibiotics such as Pen-G benzathine and Procaine, Nafcillin, Ceftazidime and Piperacillin. In addition to expanding our deep knowledge of manufacturing antibiotics and statins using our innovative bioprocesses, Centrient is already exploring new therapeutic areas by entering into short and mid-term partnerships. Our unique position makes us flexible and open to setting up reliable and valuable collaborations with small, innovative biotech companies and synergetic pharmaceutical companies. How important are R&D and innovation to the growth of your company? Judit Serra: Centrient is driven by innovation. It is in our DNA. From the beginning, we have played a leading role in the "greenification" of the industry by implementing innovative bioprocesses to produce antibiotics. We also applied this technology to the production of statins. We have established a highly technical team in the Netherlands that leads the continuous improvement of existing enzymatic processes. This allows us to position our products well in the market. We keep working daily towards making our manufacturing processes more sustainable by further reducing our manufacturing footprint. This translates into reducing our energy and water consumption in the production process. The New Pipeline program is designed to bring this technology and sustainable angle to other high-value therapeutic areas, allowing us to grow into an Active Pharmaceutical Ingredients to Finished Dosage Forms manufacturer. R&D is the key element in driving a program that's well aligned with customer and patient needs and brings additional value to all stakeholders. How has the acquisition of Astral SteriTech helped Centrient? Judit Serra: The acquisition of Astral SteriTech in 2021 has helped us add the niche but attractive segment of sterile injectable antibiotics – semi-synthetic Cephalosporin and Penicillin finished dosage forms (FDFs) – to our portfolio of products. With Astral SteriTech’s USFDA-approved manufacturing site with two manufacturing lines, we can serve customers in highly regulated markets like the United States and South Asia. In parallel, we are focusing on the vertical integration of our FDFs – meaning using our own produced intermediates and APIs for manufacturing FDFs. In this area, we also collaborate with trusted contract manufacturing organizations (CMOs) with whom we have long-term partnerships. At Centrient, we are focused on meeting our customers' expectations and serving their needs for innovative products and processes. Innovation will continue to drive growth in the generic pharmaceutical market, and Centrient is convinced to be the right partner. We invite customers seeking new added-valued collaborations in the future to reach out to us.

Impressions: 2071

#SpeakPharma With Centrient Pharmaceuticals

12 Oct 2022

Access Website

Contact Supplier

#SpeakPharma

Interphex 2024

Not Confirmed

envelop Contact Supplier

Find the latest Interview and Speak Pharma of Centrient Pharmaceuticals.